NCT04430933

A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC

A Phase 1/2 Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: NextCure, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research study is studying an investigational drug, NC318, as a possible treatment for subjects with advanced or metastatic non-small cell lung cancer in combination with chemotherapy

Conditions

• Advanced or Metastatic Solid Tumors
• Non-Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	NC318	NC318 is an experimental antibody drug that will be administered by IV infusion on the first day of each 21 day cycle
DRUG	Pemetrexed/Carboplatin	Pemetrexed/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
DRUG	Nab paclitaxel/Carboplatin	Nab-paclitaxel/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle
DRUG	Docetaxel	Docetaxel will be administered per the approved product label following the infusion of NC318 on the first day of each 21 day cycle

Timeline

• Start date: 2021-12-06
• Primary completion: 2022-06-30
• Completion: 2022-10-30
• First posted: 2020-06-16
• Last updated: 2021-08-18

Regulatory

• FDA-regulated drug study